Clinical Trial Update: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection [Phase 1]

View source ↗

Summary

This document reports a Phase 1 study to assess safety, tolerability, and pharmacokinetics of GIGA-2339 in participants with chronic hepatitis B infection, curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• GIGA-2339 (GIGA-2339)

Snippet

Sponsor: GigaGen, Inc. | Conditions: Hepatitis B Virus Infection | Phase 1 | Status: RECRUITING